MedTrace Logo

Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection

NCT04858425 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 166

Last updated 2024-10-08

Study results available
· View outcomes & findings →

Summary

This is a 2-part, 2-arm, Phase 2 , multicentre, randomized, double-blind, placebo-controlled study in adults with COVID-19 with gastrointestinal infection.

Conditions

  • Covid19

Interventions

DRUG

Niclosamide

Niclosamide tablets 400 mg 3 times daily for 14 days

DRUG

Placebo

Matched placebo tablets 400 mg 3 times daily for 14 days

Sponsors & Collaborators

  • Entero Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-30
Primary Completion
2022-06-04
Completion
2023-09-10
FDA Drug
Yes

Countries

  • United States
  • India
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04858425 on ClinicalTrials.gov